Trial Profile

A Randomised, Double-blind, Three-arm, Parallel Group, Single Dose, Phase 1 Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent, and EU-Dupixent in Healthy Adult Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Eosinophilic oesophagitis; Nasal polyps; Prurigo nodularis; Rhinosinusitis
Focus First in man; Pharmacokinetics
Sponsors Chong Kun Dang

30 Jan 2026 New trial record
29 Jan 2026 According to the Korea Bio Medical Science Institute media release, company received approval from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for the phase 1 clinical trial protocol for CKD-706.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com